Skip to main content
LUYAN PHARMA CO.,LTD logo

LUYAN PHARMA CO.,LTD — Investor Relations & Filings

Ticker · 002788 ISIN · CNE1000025W1 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2016-01-20 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002788

About LUYAN PHARMA CO.,LTD

https://www.luyan.com.cn

Luyan Pharma Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive logistics network, providing supply chain management services to healthcare institutions, including hospitals and community clinics. Its product portfolio encompasses a wide range of Western pharmaceuticals, traditional Chinese medicines, and medical equipment. In addition to wholesale distribution, the company maintains a significant presence in the retail pharmacy sector through a chain of drugstores. Luyan Pharma focuses on optimizing healthcare delivery through integrated distribution systems and value-added services, such as third-party logistics and pharmaceutical cold chain management. The organization leverages its regional market leadership to expand its service footprint and enhance the efficiency of the medical supply chain.

Recent filings

Filing Released Lang Actions
首次公开发行股票招股意向书摘要
Capital/Financing Update Classification · 95% confidence The document is titled as a "招股意向书摘要" which translates to "Prospectus Summary" or "Summary of the Initial Public Offering Prospectus." It contains detailed information about the company's IPO, including share lock-up commitments, shareholder commitments, risk factors, use of proceeds, and other IPO-related disclosures. The document is not an annual report, earnings release, or any other financial report but rather a detailed IPO prospectus summary. This type of document corresponds to a capital raising activity, specifically the initial public offering. According to the filing definitions, updates on company fundraising or capital structure changes fall under Capital/Financing Update (CAP). Therefore, this document should be classified as a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the actual document, not just an announcement of a report, so it is not RPA or RNS.
2016-01-20 Chinese
首次公开发行股票初步询价及推介公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) process of 鹭燕（福建）药业股份有限公司, including information about the preliminary inquiry, pricing, subscription procedures, investor qualifications, allotment principles, payment processes, and potential suspension conditions. It references regulatory rules and specific dates related to the IPO issuance and subscription. The content focuses on the offering and issuance of new shares, subscription rules, and allotment mechanisms rather than financial results, management changes, or legal proceedings. This type of document is a capital market announcement related to financing activities, specifically an IPO issuance and subscription process. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document is lengthy and detailed, not a brief announcement or a report publication notice, and it does not contain financial statements or earnings data, so it is not an Annual Report or Earnings Release. Hence, the classification is CAP with high confidence.
2016-01-20 Chinese
关于公司非经常性损益的审核报告
Regulatory Filings
2016-01-20 Chinese
国信证券股份有限公司关于公司申请首次公开发行股票并上市的发行保荐书
Regulatory Filings Classification · 95% confidence The document is titled as an "发行保荐书" (Sponsorship Letter) related to the initial public offering (IPO) of 鹭燕（福建）药业股份有限公司. It contains detailed information about the underwriting institution, due diligence, legal compliance, financial conditions, risk factors, and recommendations for the IPO. The document is a formal sponsorship letter issued by the underwriting securities firm to the China Securities Regulatory Commission (CSRC) supporting the company's IPO application. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement or certification. It is a regulatory filing related to the IPO process but does not fit into categories like Capital/Financing Update (CAP) or M&A Activity (TAR). Given the nature of the document as a formal regulatory submission supporting an IPO, it best fits under Regulatory Filings (RNS). The document length is substantial and contains detailed content, not just an announcement or certification, so it is not RPA or a certification. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2016-01-20 Chinese
北京市金杜律师事务所关于公司首次公开发行股票并上市的补充法律意见书（四）
Regulatory Filings Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding the initial public offering (IPO) and listing of a company, including references to audit reports, internal control reports, shareholder information, legal compliance, and corporate structure changes. It is a supplementary legal opinion related to the IPO process, referencing prior legal opinion letters and audit reports. The document is not an annual report, earnings release, or financial statement, but a legal opinion and verification document related to the IPO and listing process. It does not fit into categories like audit report standalone (AR) because it is not just an audit report, nor is it a proxy solicitation or voting results announcement. It is a legal opinion letter related to regulatory compliance and IPO issuance. Given the nature of the document as a legal opinion letter related to securities issuance and listing, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory and compliance filings that do not fit other categories.
2016-01-20 Chinese
北京市金杜律师事务所关于公司首次公开发行股票并上市的补充法律意见书（二）
Regulatory Filings Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding the company's initial public offering (IPO) and listing on the Shenzhen Stock Exchange. It discusses adjustments to the IPO plan, shareholder approvals, legal compliance, audit reports, internal control reports, shareholder commitments, and related legal and financial matters. The document references audit reports and internal control reports but is itself a legal opinion supplement related to the IPO process. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. The document is lengthy (15,000 characters) and contains substantive legal and procedural content related to the IPO issuance and listing. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance and legal opinion filing related to the IPO process, not the IPO prospectus itself or a financial report.
2016-01-20 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.